Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (4615)	6/29/1998 6:34:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 6136

Peter: No, no real opinion of CCR5. I follow it very, very, very closely, however. There's a better play, IMO, out there than PGNX. I am therefore waiting for hype to splash over PGNX, and, when/if it does, I'm ready. :-) Yeah.... the new structure of gp120 must have sent everyone scurrying. But... I like integrase as the next target with real promise. It doesn't seem rationale to me, as anything other than an "emergency use prophylactic", to try to block all the receptors on host cells. Rick